Machine learning models classify the likelihood of developing Alzheimer's.

Published Date: 05 Apr 2023

A new study suggests that once adults reach age 65, the cutoff age for Alzheimer's disease onset, the extent of their genetic risk may outweigh age as a predictor of whether they will experience the fatal brain disorder.

Read Full News

Latest News

Exploring Depressive Symptoms in Low-IQ Youth with Refractory Epilepsy Janelle L Wagner, PhD, Shannon Brothers, PhD, Cortney Wolfe-Christensen, PhD, Louie Pasculli

A trio of clinician authors provided insights on a recently published paper assessing youths with refractory epilepsy and ways to combat depressive symptoms.

High-Dose Nusinersen Gains European Commission Approval for Spinal Muscular Atrophy Louie Pasculli

The European Commission approved Biogen’s high-dose nusinersen regimen for 5q SMA, supported by DEVOTE trial data showing significantly improved motor function with a safety profile consistent with the standard-dose regimen.

NeuroVoices: Nicholas Ashton, PhD, on Advances and Challenges in Alzheimer Disease Biomarkers Nicholas Ashton, PhD, Isabella Ciccone, MPH

The senior director of the Fluid Biomarker Program at Banner Health highlighted the evolving role of blood and fluid biomarkers in Alzheimer disease research and clinical practice.

Rituximab Displays Long-Term Effectiveness for Relapsing MS Louie Pasculli

Annette Lenger-Gould, MD, PhD, lead for clinical and translational neuroscience at Kaiser Permanente, discusses findings and significance from a recently published trial assessing rituximab in patients with relapsing multiple sclerosis.

FDA Approves Subcutaneous Copper Histidinate as First Treatment for Pediatric Menkes Disease Isabella Ciccone, MPH

The FDA approved Sentynl Therapeutics’ copper histidinate for the treatment of pediatric Menkes disease, a rare genetic neurodegenerative disorder, following an earlier complete response letter.

Stereotactic Radiosurgery: Advancing Precision in Treating Neurological Disorders Lilyana Angelov, MD

The director of Cleveland Clinic's Gamme Knife Center and Head Section of Spine Tumors writes about how stereotactic radiosurgery has transformed modern neurology and neurosurgery

Todays Updates

Phase 3 VALOR Data Further Support Tofersen’s Impact on ALS Disease Progression, Survival Marco Meglio

Published phase 3 data in JAMA Neurology highlighted tofersen's potential to slow ALS progression and improve survival, marking a breakthrough in SOD1-ALS treatment.

Adding CBT to Quetiapine Significantly Reduces Suicide Risk in Mood Disorders

Adding CBT to Quetiapine Significantly Reduces Suicide Risk in Mood Disorders

Iron Polymaltose Complex Outperforms Liposomal Iron in Pediatric CKD Anemia

Iron Polymaltose Complex Outperforms Liposomal Iron in Pediatric CKD Anemia

FDA Requests Removal of Suicidal Ideation and Behavior Warning From GLP-1 RA Therapies

FDA Requests Removal of Suicidal Ideation and Behavior Warning From GLP-1 RA Therapies

Melanoma Surgery Delay After 4 Weeks Post-Diagnosis Decreases Survival Rates

Melanoma Surgery Delay After 4 Weeks Post-Diagnosis Decreases Survival Rates

Todays Updates

Phase 3 VALOR Data Further Support Tofersen’s Impact on ALS Disease Progression, Survival Marco Meglio

Published phase 3 data in JAMA Neurology highlighted tofersen's potential to slow ALS progression and improve survival, marking a breakthrough in SOD1-ALS treatment.

Adding CBT to Quetiapine Significantly Reduces Suicide Risk in Mood Disorders

Adding CBT to Quetiapine Significantly Reduces Suicide Risk in Mood Disorders

Iron Polymaltose Complex Outperforms Liposomal Iron in Pediatric CKD Anemia

Iron Polymaltose Complex Outperforms Liposomal Iron in Pediatric CKD Anemia

FDA Requests Removal of Suicidal Ideation and Behavior Warning From GLP-1 RA Therapies

FDA Requests Removal of Suicidal Ideation and Behavior Warning From GLP-1 RA Therapies

Melanoma Surgery Delay After 4 Weeks Post-Diagnosis Decreases Survival Rates

Melanoma Surgery Delay After 4 Weeks Post-Diagnosis Decreases Survival Rates

Latest News

A trio of clinician authors provided insights on a recently published paper assessing youths with refractory epilepsy and ways to combat depressive symptoms.

The European Commission approved Biogen’s high-dose nusinersen regimen for 5q SMA, supported by DEVOTE trial data showing significantly improved motor function with a safety profile consistent with the standard-dose regimen.

The senior director of the Fluid Biomarker Program at Banner Health highlighted the evolving role of blood and fluid biomarkers in Alzheimer disease research and clinical practice.

Annette Lenger-Gould, MD, PhD, lead for clinical and translational neuroscience at Kaiser Permanente, discusses findings and significance from a recently published trial assessing rituximab in patients with relapsing multiple sclerosis.

The FDA approved Sentynl Therapeutics’ copper histidinate for the treatment of pediatric Menkes disease, a rare genetic neurodegenerative disorder, following an earlier complete response letter.

The director of Cleveland Clinic's Gamme Knife Center and Head Section of Spine Tumors writes about how stereotactic radiosurgery has transformed modern neurology and neurosurgery

News All Time

Oral Anticoagulants Do Not Raise ARIA Risk of Anti-Amyloid Alzheimer Therapies, Study Shows Louie Pasculli

A review of clinical trial and real-world data found no evidence that oral anticoagulants increase brain imaging abnormalities in patients treated with lecanemab or donanemab for early Alzheimer disease.

NeurologyLive® Friday 5 — January 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 9, 2026.

BMB-101 Heads for Registrational Trials Following Positive Phase 2 Data in Absence Seizures, Developmental Encephalopathies Marco Meglio

Bright Mind Biosciences reveals promising results for BMB-101 in treating drug-resistant seizures, paving the way for future clinical trials.

Episode 158: Bexicaserin, the PACIFIC Trial, and Treating Developmental Epileptic Encephalopathies Marco Meglio, Johannes Streffer, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Johannes Streffer, MD. [LISTEN TIME: 14 minutes]

Key Neurology Trial Readouts to Watch in Early 2026 Isabella Ciccone, MPH

Review upcoming clinical trials with data readouts expected in the first half of 2026, providing updates relevant to ongoing research and clinical practice in neurology.

NeuroVoices: Christina Briscoe, MD; Emily Spelbrink, MD, PhD, on Addressing Equity Gaps in Infantile Epileptic Spasms Syndrome Marco Meglio, Christina Briscoe, MD, Emily Spelbrink, MD, PhD

A pair of pediatric epileptologists highlight the systemic and patient level factors driving inequities in infantile epileptic spasms syndrome care and outline paths toward more equitable diagnosis and treatment.

GLP-1 Liraglutide Displays Effectiveness as Migraine Treatment in Early-Stage Study Louie Pasculli

In a pilot study, liraglutide, a drug used for diabetes and weight-loss, significantly reduced headache days in patients with obesity and chronic or high-frequency migraine, suggesting a potential new preventive therapy.

Fenfluramine Treatment Leads to Long-Term Improved Everyday Executive Functioning in Lennox-Gastaut Syndrome Marco Meglio

A recent analysis reveals fenfluramine's positive effects on executive functioning in adults with Lennox-Gastaut syndrome, independent of seizure reduction.

NeurologyLive®: Charting our 2026 Conference Coverage Louie Pasculli

Follow NeurologyLive's conference journey in 2026, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

AES Poster Shines Light on Positive Phase 3 GEMZ Study of Fenfluramine in CDKL5 Deficiency Disorder Marco Meglio

Fenfluramine shows significant seizure reduction in CDKL5 deficiency disorder, offering hope for families facing treatment-resistant epilepsy challenges.

Fenfluramine’s Safety Profile Consistent in Long-Term Extension Dravet and Lennox-Gastaut Syndrome Studies Isabella Ciccone, MPH

Final safety data from an open-label study presented at AES 2025 supported long-term fenfluramine use in pediatric and adult patients with Dravet syndrome or Lennox-Gastaut syndrome.

Claims Study Highlights Persistence and Reasons for Fenfluramine Use in Lennox-Gastaut Syndrome Marco Meglio

An AES study revealed the real-world persistence of fenfluramine in treating Lennox-Gastaut syndrome, highlighting patient demographics and treatment trends.

FDA Action Update, December 2025: Acceptance, Approval, and Clearance Isabella Ciccone, MPH

Catch up on any of the neurology news headlines you may have missed in December 2025, compiled into 1 place by the NeurologyLive® team.

FDA Approves Generic Glatiramer Acetate Injection for Multiple Sclerosis Treatment Marco Meglio

The newly approved generic product is expected to perform like other high-quality glatiramer acetate generics, with differences confined mainly to the manufacturer and device, not mechanism or dosing.

Semaglutide Linked to Improved Neurological Outcomes in Large Vessel Occlusion Without IV Thrombolysis Marco Meglio

A recent trial reveals semaglutide's potential for neurological improvement in stroke patients, despite no overall functional recovery benefits.

This Week on NeurologyLive® — January 5, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Recommended News For You

No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer

Primary Sjögren's syndrome patients' B-Cell Stimulating Factors are associated with the growth of lymphomas.

Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?

Through the activation of bitter taste receptors, lidocaine has the potential to kill some cancer cells.

June 20, 2023, Health Bulletin No. 12.

Children with cancer tumors lacking DNA repair may benefit from olaparib combined with ceralasertib.

Daily physical activity, even at light intensities, linked to lower cancer risk

Recommended Articles For You

Understanding Iron Saturation Levels in Your Blood  

Anesthetic Techniques and Strategies in Cancer Surgery: Unveiling the Impact on Oncological Outcomes 

A Glimmer of Hope: The Predictive Power of Liquid Biopsy and AI in Palliative Oncology 

Ethics of Experimental Oncology: Case Study on Autonomy, Consent & Decision-Making 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study sheds light on challenges for women of color after breast cancer surgery

2.

Big PFS Increase in Advanced Neuroendocrine Tumors With Combination Therapy

3.

FDA Approves CAR-T Product Use for Myeloma Early.

4.

How 7,000 steps a day could help reduce your risk of cancer

5.

Patients with metastatic breast cancer can predict their response to HER2-targeted therapy using whole-body PET/CT.

1.

Revolutionizing Cancer Treatment with Trilaciclib: How a New Drug is Transforming Outcomes

2.

Hope for a Cure: Exploring New Treatments for Sickle Cell Anemia

3.

Liquid Biopsies and ctDNA: Transforming Cancer Detection, Monitoring, and Clinical Decisions

4.

How Bispecific Antibodies are Redefining Medical Oncology in the US - A 2025 Review

5.

How is Digital Innovation Revolutionizing Gynecologic Oncology Treatment and Patient Engagement?

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

2.

Navigating the Complexities of Ph Negative ALL - Part VII

3.

Updates on Standard V/S High Risk Myeloma Treatment

4.

Oropharyngeal Cancer in Relation to HPV Status

5.

Efficient Management of First line ALK-rearranged NSCLC - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot